The Kinetics and Reproducibility of 18F NaF for Oncology Using Current PET Camera Technology

K.A. Kurdziel, J.H. Shih, A.B. Apolo, L Lindenberg, E Mena, Y.Y. McKinney, S.S. Adler, B Turkbey, W Dahut, J.L. Gulley, R.A. Madan, O Landgren and P.L. Choyke |  2012-06-22

This study assesses18F NaF for recommended dose, optimal uptake period and reproducibility, using current-generation PET/CT scanners. Images obtained with modest radiation exposure resulted in highly reproducible imaging parameters.

For Intravenous Use


Sodium Fluoride F 18 Injection is a radioactive diagnostic agent for positron emission tomography (PET) indicated for imaging of bone to define areas of altered osteogenic activity.



Allergic Reactions: As with any injectable drug, allergic reactions and anaphylaxis may occur. Emergency resuscitation equipment and personnel should be immediately available.


Cancer Risk: Sodium fluoride F18 injection may increase the risk of cancer. Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker.


Adverse Reactions: No adverse reactions have been reported for Sodium Fluoride F 18 based on a review of the published literature, publicly available reference sources, and adverse drug reaction reporting systems.


Siemens' PETNET Solutions is a manufacturer of Sodium Fluoride F 18 Injection (18F NaF). Indication and important safety information as approved by the US Food and Drug Administration can be found at the links below for sodium fluoride 18F NaF, adult dose 8-12 mCi, administered by intravenous injection.

Related Articles